Author: therawinformant

from Yahoo Finance https://ift.tt/2WVLU6n

On Wednesday, Jerome Powell shared prepared remarks regarding the future outlook for the U.S. economy, but admits there are ‘longer-term concerns.’ Andrew Slimmon, Morgan Stanley Investment Management Managing Director and Sr. Portfolio Manager, joins Yahoo Finance to discuss.

from Yahoo Finance https://ift.tt/3cvQb6T

Last week saw the newest first-quarter earnings release from UnitedHealth Group Incorporated (NYSE:UNH), an important…

from Yahoo Finance https://ift.tt/2WP3oRR

(Bloomberg Opinion) — As panic-ridden consumers stock up on essentials, kitchen pantries are looking like a blast from the processed-food past: boxes of Kraft macaroni and cheese, cans of Bumble Bee tuna, Kellogg’s Frosted Flakes, Shake ‘N Bake, etc. Brands of yesteryear that had been struggling to find their place in a new health-conscious society are suddenly having a moment once again. But a moment is probably all it will be, not a new normal, which is why packaged-food companies shouldn’t get too comfortable about their comfort food.The Covid-19 pandemic and shelter-in-place orders have led consumers to revert to old ways of shopping in search of ready-made meals and foods with long shelf lives. Parents who are working from home during this time are multitasking like never before, taking on the role of cook, housekeeper, teacher, disciplinary and full-time employee all at once in a Groundhog Day-like loop. As such, traditional meal times have blurred, and in some cases snacks are replacing them, according to research by Euromonitor International. This explains the resurgence of companies such as General Mills Inc., whose brands include Annie’s, Betty Crocker, Cheerios, Pillsbury and Totino’s pizza rolls. Its U.S. retail sales surged 45% in March and 32% in April. To put that into context, the company’s average annual growth rate was just 1.5% over the last decade.In the U.S., the food category that saw the biggest uptick in demand during the week ended April 25 was bread crumbs and other mixes for coating foods, followed by dough and batter products, according to Nielsen tracking. That bodes well for brands such as Shake ‘N Bake, whose parent company, Kraft Heinz Co., just reported its first quarterly sales boost in more than a year.In recent years leading up to this crisis, Campbell Soup Co. was perhaps the hardest hit by changing consumer tastes and demand for fresher foods. The company lost $8.6 billion of shareholder value between mid-2016 and mid-2018, a performance that saw its last CEO out. But amid the shutdowns, Campbell’s stock has been staging a recovery and is trading near its highest price in three years. Kellogg Co. has called this a “reappraisal opportunity” for cereal — a chance to persuade shoppers to give its sugary products another try. Speaking during Kellogg’s recent earnings call, CEO Steve Cahillane said: “Consumers rediscovering these benefits could be very positive for this category, and we plan to seize this opportunity.”But careful, Kellogg. The fact of the matter is, even if the coronavirus leaves a lasting impression on certain aspects of consumer behavior, the dislocation taking place at supermarkets is shaping up to be more of a temporary phenomenon driven in part by food shortages and fear. Consider the absurdity that about 20% of store-bought noodles have been out of stock in the U.S. since mid-March, when the earliest lockdowns began, according to Euromonitor. That’s on the same level as toilet paper shortages. Even baker’s yeast, of all things, is still sold out in many places. But just like we’re not all going to turn our YouTube-taught hair-cutting skills into new careers, most of us won’t keep up such rigorous home training for “The Great British Bake Off,” either.Consumers generally still want fresh, less-processed and healthier-sounding foods. Nielsen is already seeing this in surveys of other countries: In France, shoppers continue to seek out organic items, while Asian consumers say healthy eating has become more of a priority after the virus. And if the post-virus rise of virtual fitness classes is any indication, health and wellness is still top of mind for lots of people.It’s true, families need convenience right now and many are looking to save money as the U.S. dips deeper into a recession and the unemployment rate soars above 14%. That’s partly why seemingly dated grocery products are coming back into favor. They also provide a sense of nostalgia and familiarity at a time when life has been thrown off course.Another significant factor is all the bulk-buying: Wholesale stores such as Costco and BJ’s offer a much more limited variety that tends to be dominated by big-name food brands (although new trendier products are increasingly making their way in). Buying fresh and organic also usually costs more and sells in smaller packages. Over the next few months, Euromonitor analysts expect a greater shift toward more affordable items, private-label brands and bulk purchases.That does create an opportunity for the food giants. A downside to stocking up is all the packaging and cardboard that accumulates, taking up space. It’s an annoyance that companies could try to resolve if sheltering at home is to become a more regular part of life over the next couple of years rather than a distant memory. As U.S. states reopen, though, consumers will probably start to go back to their old routines — or at least some version of them. A bit of the doomsday-prepper mentality may remain, leading more households to keep their cupboards stocked with nonperishables, just in case. But it’s fair to say that the future of the supermarket isn’t Kraft mac and cheese or Campbell’s canned soup. It would be short-sighted to interpret this moment as a rebuke of their innovation efforts. If anything, it’s a time to step it up. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Tara Lachapelle is a Bloomberg Opinion columnist covering the business of entertainment and telecommunications, as well as broader deals. She previously wrote an M&A column for Bloomberg News.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/2T40O9p

Yahoo Finance’s Brian Cheung breaks down the details from Jerome Powell’s prepared remarks on Wednesday morning.

from Yahoo Finance https://ift.tt/2YYHTR7

Yahoo Finance’s Brian Sozzi and Alexis Christoforous break down the market action with Alicia Levine, BNY Mellon Chief Strategist.

from Yahoo Finance https://ift.tt/2Aq087X

The Brink's Company (NYSE:BCO) is about to trade ex-dividend in the next 3 days. This means that investors who…

from Yahoo Finance https://ift.tt/2LfUGXs

COVID-19 has left the U.S. economy reeling, yet Wall Street is pushing forward. Unemployment has reached alarming levels, with the loss of 20.5 million jobs in April bringing the U.S. unemployment rate to 14.7%, but the S&P 500 has staged somewhat of a recovery. While the index dipped Tuesday as investors weighed reopening efforts against fears of a second wave of infections, it has gained about 30% since hitting lows in March.So, what’s driving this stock market disconnect? Mike Wilson, Morgan Stanley's chief U.S. equity strategist, argues that investors are betting on a future recovery, with these bets being primarily fueled by concrete actions rather than the unknown. Additionally, he points out that market watchers believe the rebound will be “V-shaped”, the most ambitious form of an economic recovery.“Our client conversations have changed dramatically over the past month, shifting from whether we will have a re-test of the March lows to what does the shape of a recovery look like. Our view is that we will see a sustainable V-shaped recovery,” Wilson commented. He added, “… primarily because history tells us this is the way it always looks and feels in a recession — a highly uncertain recovery path, pessimistic investors, and volatile asset markets reacting to daily updates about the exogenous shock that got us here in the first place.”Taking Wilson’s statements to heart, we used TipRanks’ database to take a closer look at two stocks that have received Morgan Stanley's stamp of approval. TipRanks revealed that both Buy-rated names have amassed support from other analysts and boast over 25% upside potential. Zentalis Pharmaceuticals (ZNTL)Focused on the creation of differentiated small molecule treatments that target biological pathways of cancer, Zentalis believes it has developed an integrated approach that will allow it to overcome the limitations of current cancer therapeutics. Morgan Stanley highlights the speed of its pipeline advancement and the quality of its technology as making this company a standout in a crowded space.Representing the firm, five-star analyst Matthew Harrison cites ZNTL’s four INDs in a short period of time as proof of its development capabilities. “Small molecule targeted oncology is an attractive area for investment as initial results on efficacy and safety can quickly de-risk an asset and lead to fast approvals. Management has built a top-notch, differentiated chemistry group which has allowed Zentalis to quickly build a large pipeline against key targets,” he explained.Looking specifically at its lead asset, ZN-c5, a small molecule selective estrogen receptor degrader (SERD) designed for use in breast cancer, Harrison points out that it has already demonstrated clinically and preclinically low levels of major side effects as well as robust efficacy. This is important because while oral SERDs could be used across multiple stages of breast cancer and are more convenient than injectables, other oral SERDs in development have caused side effects like rash, diarrhea and vomiting. Based on all of this, the analyst thinks the opportunity for ZN-c5 could land in the billions.The good news doesn’t stop there. Harrison stated, “Importantly, the rest of the pipeline is robust, offering additional compelling targets.” In particular, he estimates that its Wee1 (ZN-c3) candidate could see peak sales hit $1 billion. When it comes to Bcl-2 (ZN-d5), Harrison argues that this therapy is a de-risked target with only one key competitor, with it possibly allowing ZNTL to differentiate itself. It should also be noted that the company has a third generation EGFR inhibitor that could be used alongside its SERD.It should come as no surprise, then, that Harrison joined the bulls. To kick off his coverage, he put an Overweight call and $45 price target on the stock. Should this target be met, a twelve-month gain of 26% could be in store. (To watch Harrison’s track record, click here) Does the rest of the Street agree with Harrison? With 100% Street support, or 4 Buy ratings to be exact, the consensus is unanimous: ZNTL is a Strong Buy. In addition, the $43.67 average price target implies 23% upside potential. (See Zentalis stock analysis on TipRanks)Quest Diagnostics Inc. (DGX)When it comes to laboratory diagnostic information services company Quest Diagnostics, Morgan Stanley has had a change of heart. Back in March, the firm downgraded the stock due to the overwhelming headwinds it thought couldn’t be offset by COVID-19 testing, but now it’s singing a different tune.Weighing in on DGX for the firm, five-star analyst Ricky Goldwasser argues that expanded testing guidelines as well as new market opportunities bode well for the company. Even though Wall Street has been laser-focused on the opportunity related to serology testing recently, based on Goldwasser’s analysis, the COVID-19 diagnostic testing opportunity could be two times larger if testing is added as part of a pre-elective procedure routine. She also points out that since March, supply shortages have limited COVID-19 testing, which in turn has spurred restrictive testing guidelines in an effort to save supplies.Expounding on this, Goldwasser stated, “Over time, as supplies become more available, testing guidelines are starting to expand. We expect Quest Diagnostics to meaningfully benefit from the market evolution to phase II of the testing paradigm and out of the four walls of the hospital. Our analysis suggests COVID-19 diagnostics could translate to ~689 million revenue opportunity and $372 million in EBIT through 2021.”That’s not to say serology testing isn’t important for DGX, with Goldwasser noting it’s a “critical component in reopening business.” She added, “Employers who are developing their return to work programs are working with the national labs to create testing programs. While the opportunity is going to be split among other supply chain participants (drug retail chains included), we estimate this as a $335 million revenue opportunity for Quest through the fall of 2020 helping to offset some of the declines in core testing.”All of the above prompted Goldwasser to upgrade her rating from Equal-weight to Overweight. On top of this, she bumped up the price target from $95 to $139. This new target suggests shares could surge 29% in the next twelve months. (To watch Goldwasser’s track record, click here) Looking at the consensus breakdown, DGX has been assigned 5 Buys, 8 Holds and 1 Sell in the last three months. As a result, it earns a Moderate Buy consensus rating. At $111.43, the average price target puts the upside potential at a modest 3.4%. (See Quest Diagnostics stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

from Yahoo Finance https://ift.tt/2SZdIW4

Today we're going to take a look at the well-established CenturyLink, Inc. (NYSE:CTL). The company's stock saw a…

from Yahoo Finance https://ift.tt/3dCZdPH

Powell said in prepared remarks Wednesday that the depth and length of a recession can “leave behind lasting damage," suggesting that those inside the Fed see slim chances of a V-shaped recovery. 

from Yahoo Finance https://ift.tt/2T1rnfu